In the 90’s, big Pharma kept all research functions within its corporate walls and since then innovation has been catalyzed through new models totally virtual, hybrid and open innovation.
In this o2h ChaiTime, we examined these models to determine if these are effective and how are they valued by investors and acquirers such as big pharma.
MAtt is CEO and Co-Founder of Inflazome, he started the virtual company in 2016 and in super-fast time this month sold the business to Roche for $450m upfront with further milestone payments.
Harren is President and Co-Founder of Astex Pharmaceuticals, a therapeutics business that he later sold to Otsuka for $886m.
Professor Chas Bountra is Pro Vice-Chancellor for Innovation at the University of Oxford. he is Associate Member of the Department of Pharmacology at the University of Oxford.
A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector.